Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 4/20 | 0.50 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 4/20 | 0.39 |
| ▸ | PPARG | P37231 | 4/20 | 0.39 |
| ▸ | THRA | P10827 | 3/20 | 0.39 |
| ▸ | RXRA | P19793 | 2/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28129197 | 0.84 | HSD17B10 (0.36) | TTRTHRBPPARGTHRARXRA | |
| SCHEMBL28129730 | 0.84 | CHEK1 (0.46) | TTRALBTHRBPPARGTHRA | |
| SCHEMBL8773696 | 0.76 | TTR (0.52) | TTRALBTHRBPPARGTHRA | |
| SCHEMBL1126255 | 0.76 | TTR (0.52) | TTRALBTHRBPPARGTHRA | |
| SCHEMBL10551451 | 0.74 | CA1 (0.50) | TTRMEN1KMT2ALMNACYP2C9 | |
| SCHEMBL6104943 | 0.73 | THRB (0.40) | THRBPPARGTHRARXRAMEN1 | |
| SCHEMBL8961865 | 0.73 | XDH (0.47) | TTRALBPPARGRXRAMEN1 | |
| SCHEMBL3205151 | 0.72 | SELP (0.41) | LMNAHTTCYP2C9HIF1AADRB2 | |
| SCHEMBL12514479 | 0.72 | TTR (0.48) | TTRALBTHRBPPARGTHRA | |
| SCHEMBL8773681 | 0.72 | TTR (0.48) | TTRALBTHRBPPARGTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004062-A1 | Compounds for inhibiting insulin secretion and methods related thereto | MITOKOR (US) | 2006-01-05 | — | — | US | disclosed |
| US-6958352-B2 | Compounds for inhibiting insulin secretion and methods related thereto | SMITHKLINE BEECHAM CORPORATION (US) | 2005-10-25 | — | — | US | disclosed |
| EP-1472214-A2 | COMPOUNDS FOR INHIBITING INSULIN SECRETION AND METHODS RELATED THERETO | SmithKline Beecham Corporation (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040044049-A1 | Compounds for inhibiting insulin secretion and methods related thereto | MITOKOR | 2004-03-04 | — | — | US | disclosed |
| WO-2003066035-A2 | COMPOUNDS FOR INHIBITING INSULIN SECRETION AND METHODS RELATED THERETO | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004062-A1 | Compounds for inhibiting insulin secretion and methods related thereto | IAPP, GPR119, INSR | TTR 2355/4885ALB 3816/4885THRB 67/4885 |
| US-20040044049-A1 | Compounds for inhibiting insulin secretion and methods related thereto | IAPP, GPR119, IRS1 | TTR 3128/4885ALB 4174/4885THRB 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.